GRFS Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals Plc has a net margin of 6.35% compared to Grifols SA's net margin of --. Grifols SA's return on equity of 6.37% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.

Grifols SA has a consensus price target of $11.10, signalling upside risk potential of 34.71%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $7.02 which suggests that it could grow by 704.13%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Grifols SA, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Grifols SA.

Grifols SA has a beta of 0.703, which suggesting that the stock is 29.678% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.106, suggesting its more volatile than the S&P 500 by 10.59%.

Grifols SA has a quarterly dividend of $0.18 per share corresponding to a yield of 2.14%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.

Grifols SA quarterly revenues are $2.3B, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Grifols SA's net income of $146.4M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Grifols SA's price-to-earnings ratio is 12.22x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.66x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of 6.35% compared to Grifols SA's net margin of -253.13%. Grifols SA's return on equity of 6.37% beat Cellectis SA's return on equity of -65.19%.

Grifols SA has a consensus price target of $11.10, signalling upside risk potential of 34.71%. On the other hand Cellectis SA has an analysts' consensus of $7.25 which suggests that it could grow by 112.61%. Given that Cellectis SA has higher upside potential than Grifols SA, analysts believe Cellectis SA is more attractive than Grifols SA.

Grifols SA has a beta of 0.703, which suggesting that the stock is 29.678% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.907, suggesting its more volatile than the S&P 500 by 190.653%.

Grifols SA has a quarterly dividend of $0.18 per share corresponding to a yield of 2.14%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Grifols SA quarterly revenues are $2.3B, which are larger than Cellectis SA quarterly revenues of $10.4M. Grifols SA's net income of $146.4M is higher than Cellectis SA's net income of -$26.3M. Notably, Grifols SA's price-to-earnings ratio is 12.22x while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.66x versus 4.70x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of 6.35% compared to Grifols SA's net margin of --. Grifols SA's return on equity of 6.37% beat DBV Technologies SA's return on equity of -217.87%.

Grifols SA has a consensus price target of $11.10, signalling upside risk potential of 34.71%. On the other hand DBV Technologies SA has an analysts' consensus of $39.89 which suggests that it could grow by 89.39%. Given that DBV Technologies SA has higher upside potential than Grifols SA, analysts believe DBV Technologies SA is more attractive than Grifols SA.

Grifols SA has a beta of 0.703, which suggesting that the stock is 29.678% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.942, suggesting its less volatile than the S&P 500 by 194.186%.

Grifols SA has a quarterly dividend of $0.18 per share corresponding to a yield of 2.14%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Grifols SA quarterly revenues are $2.3B, which are larger than DBV Technologies SA quarterly revenues of --. Grifols SA's net income of $146.4M is higher than DBV Technologies SA's net income of -$44.8M. Notably, Grifols SA's price-to-earnings ratio is 12.22x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.66x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk A/S has a net margin of 6.35% compared to Grifols SA's net margin of 33.98%. Grifols SA's return on equity of 6.37% beat Novo Nordisk A/S's return on equity of 62.44%.

Grifols SA has a consensus price target of $11.10, signalling upside risk potential of 34.71%. On the other hand Novo Nordisk A/S has an analysts' consensus of $47.36 which suggests that it could grow by 28.08%. Given that Grifols SA has higher upside potential than Novo Nordisk A/S, analysts believe Grifols SA is more attractive than Novo Nordisk A/S.

Grifols SA has a beta of 0.703, which suggesting that the stock is 29.678% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.371%.

Grifols SA has a quarterly dividend of $0.18 per share corresponding to a yield of 2.14%. Novo Nordisk A/S offers a yield of 4.81% to investors and pays a quarterly dividend of $1.22 per share. Grifols SA pays -- of its earnings as a dividend. Novo Nordisk A/S pays out 36.87% of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Grifols SA quarterly revenues are $2.3B, which are smaller than Novo Nordisk A/S quarterly revenues of $12.3B. Grifols SA's net income of $146.4M is lower than Novo Nordisk A/S's net income of $4.2B. Notably, Grifols SA's price-to-earnings ratio is 12.22x while Novo Nordisk A/S's PE ratio is 10.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.66x versus 3.52x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.